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Early Identiﬁcation of Type 2 Diabetes
Policy should be aligned with health systems strengthening
M
orethan60%oftheestimated285
million people with diabetes glo-
bally are in low- and middle-
income countries (LMICs) (1). Largely
driven by the growth of type 2 diabetes,
the numbers of people with diabetes
worldwide is projected to touch at least
450 million by 2030, with the biggest in-
crease happening in LMICs and substan-
tially driven by populous Asian countries
like India and China (1). Recent data in-
dicateanurbandiabetesage-standardized
prevalence of 11.4% in China (2) and
9.1–13.0%inIndiaintheongoingIndian
Council of Medical Research–India Dia-
betes (ICMR–INDIAB) study (V.M. An-
jana, A. Mohan, personal communi-
cation). Furthermore, the prevalence of di-
abetes may be as high as 8.2% among rural
residents in China (2) and may vary from
2.8 to 11.9% in rural India, depending on
thelevelofeconomicdevelopment(ICMR–
INDIABstudy).Importantly,ahighpropor-
tion of people with type 2 diabetes (50–
70% in China [2,3] and 30–80% in India
[ICMR–INDIAB study]) remain undiag-
nosed and thus untreated. Should there,
therefore,beanactivepolicytoidentifydys-
glycemia and diabetes early?
Asundiagnoseddiabetesisfrequently
associated with potentially preventable
costly diabetes complications and con-
comitant cardiovascular risk factors (4–
6), a policy of early identiﬁcation through
systematic or opportunistic means may
have some appeal. Indeed, the merits or
otherwise of a screening policy for diabe-
teshavebeenpreviouslyreviewedandas-
sessed (7). The consensus thus far has
been that type 2 diabetes meets many of
criteria for screening, namely, the burden
is large, the natural history is well under-
stood, there is a long latent period, and
effective and cost-effective treatments for
diabetes are available. However, three
challenges still remain: 1) a reliable, high-
performance, convenient, low-cost
screening test that can be universally ap-
pliedhasbeenlacking;2)directevidenceof
the beneﬁts and costs of screening are hard
to obtain; and 3) the capacity of health sys-
tems worldwide, especially in LMICs, to
carry out identiﬁcation and then to manage
the potentially huge new burden of newly
identiﬁed cases is a concern.
The challenge of a reliable, conve-
nient, low-cost test that may be used
widely, especially in LMICs, is potentially
soluble. Ritchie el al. (8), for example,
present data in this month’s issue of Dia-
betes Care indicating that a point-of-care
(POC) blood test could be a simple and
reliable tool for identifying undiagnosed
diabetes. In a population-based study in
resource-poor rural South India, Ritchie
el al. (8) evaluated a ﬁnger-prick fasting
capillary POC against fasting venous
plasma glucose by systematically screening
arandomsampleof1,085participantsaged
30 years and older, representing a popula-
tion of 75,089 from 20 villages. Diabetes
was deﬁned according to the 1999 World
HealthOrganization(WHO)criteriaoffast-
ing venous plasma glucose of 126 mg/dl.
They found that the POC fasting capillary
test that they used had an area under the
curveof0.87fordetectingdiabetesandwas
signiﬁcantly better than risk scoring tools
that use common clinical variables (age,
BMI, hypertension, waist circumference,
area under the curve of 0.69). Further-
more, adding clinical variables to their
POC fasting capillary test did not signiﬁ-
cantly improve the discriminatory capa-
bility beyond that achieved with the POC
glucose alone.
An oral glucose tolerance test or fast-
ing plasma glucose are cumbersome and
inconvenient, and the A1C test is expen-
sive and poses special problems with
standardization and performance. All of
these tests are complex and require
skilledhealthcareworkersandlaboratory
facilities for the analysis of samples,
which are often a challenge in resource-
poor settings. While there have been nu-
merous attempts to develop simple paper
and pencil tests to screen for diabetes,
these have remained suboptimal, and
their performance varies widely by popu-
lation (9). Therefore, as suggested by
WHO, a simple and reliable POC capil-
lary glucose test offers major advantages,
but its cost and cost-effectiveness are yet
to be ascertained (10).
TheseresultsfromRitchieetal.addto
the literature on POC capillary glucose
tests in resource-poor settings (11,12).
While data from Ritchie et al. (8) indicate
arealisticpotentialtodevelopreliableand
convenient low-cost POC tests to detect
diabetes, three issues remain to be re-
solved. Firstly, the performance of capil-
lary POC tests may differ by population
characteristics or disease prevalence. For
example,POCglucoseperformedwellfor
detecting diabetes in an Australian indig-
enous population, but was less discrimi-
natory in a study among Maori (11,12).
Further investigations into evaluating a
variety of cut points for capillary POC
tests in diverse populations may help.
Secondly, the costs of POC tests for mass
applicationinLMICsremainamajorcon-
cern. Ritchie et al. indicate that the POC
capillary test, at less than $2 (U.S.) per
test, may be inexpensive, but the cost of
these tests may need to be many-fold
lower before they can be considered for
broader use in LMICs. Partnerships with
manufacturers in developing countries
may help to lower the costs as has been
done with cervical cancer tests and with
vaccines (13,14). Thirdly, how a POC
bloodtestmaybecombinedwithcheaper
paperandpencilriskscoresremainstobe
fully explored. While Ritchie et al. (8)
point out that their POC capillary test is
better than India-speciﬁc risk scores, the
latter are only a ﬁrst step to improve the
cost-effectiveness of the identiﬁcation of
undiagnosed diabetes.
Given the ethical and logistical chal-
lenges of conducting a randomized con-
trolled trial comparing a screening policy
versus control, direct evidence for the ben-
eﬁts and costs of screening for diabetes is
unlikely to be produced. Recently, how-
ever,anumberofstudiesindicatethatapol-
icy of early identiﬁcation of type 2 diabetes
may be worth seriously considering. The
Anglo-Danish-Dutch study of Intensive
Treatment In peOple with screeN-detected
diabetes in primary care (ADDITION) trial,
whose results were recently reported at an
international conference (15), found that
primary-care stepwise screening for type 2
diabetes is feasible in settings with good in-
frastructure and can identify people with
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Furthermore, treatment in people with
screen-detecteddiabetesisalsofeasible,and
even in a group that received only routine
care, cardiovascular risk factors improved
inthe5yearsfollowingdetectionscreening.
The screen-detected patients who received
intensive treatment, however, had greater
improvements in prescribed treatment, in
levels of risk factors, and also a 12% reduc-
tion in cardiovascular death, a 30% reduc-
tioninnonfatalmyocardialinfarction,anda
21% decrease in revascularization, but a
nonsigniﬁcant 17% reduction in the inci-
dence of a composite cardiovascular pri-
mary end point over 5 years. Earlier reports
from the ADDITION trial have also indi-
cated that screening for type 2 diabetes is
unlikely to be associated with adverse con-
sequences such as anxiety or false reassur-
ance (16). The ADDITION trial was,
however,conductedinthreecountrieswith
established and elaborate nationalized
health systems; therefore, translation of
these ﬁndings into LMICs will remain a
challengethatrequiresacombinationofev-
idence, resources, and socio-political will.
In a simulation model using person-
speciﬁcdatafromarepresentativesample
of the U.S. population, Kahn et al. (17)
compared eight different screening strat-
egies for type 2 diabetes with a no-
screening control strategy. Compared
withnoscreening,allsimulatedscreening
strategies reduced the incidence of myo-
cardial infarction (3–9 events prevented
per 1,000 people screened) and diabetes-
related microvascular complications (3–9
events prevented per 1,000 people
screened), and increased the number of
quality-adjusted life-years (93–194 un-
discounted quality-adjusted life-years)
added over 50 years. Screening for type 2
diabetes was found to be especially cost-
effective when started between 30 and 45
years of age, with screening repeated ev-
ery 3–5 years (17). An earlier simulation
study, using the Centers for Disease Con-
trolandPrevention–ResearchTriangleIn-
stitute (CDC–RTI) diabetes model, had
also found opportunistic screening to be
within the range of cost-effectiveness
whenappliedtoyoungerpopulationsand
minority groups in the U.S. (18).
An additional consideration when
thinking about screening for type 2 dia-
betes is the possibility of coupling it with
earlyidentiﬁcationofnondiabeticdysgly-
cemia, and there are arguments for such
an approach. The evidence for the effec-
tiveness and cost-effectiveness of inten-
sive lifestyle intervention or metformin
among people with dysglycemia is very
strong (19,20). Research also shows that
nurses or university graduates can be
trained in LMICs to deliver simple and
effective preventive health messages to
people with dysglycemia and at risk of
diabetes (21). Implementation of primary
prevention will, however, require an ac-
tive approach to the identiﬁcation of dys-
glycemia, which will also identify
undiagnosed diabetes. The recently pub-
lished results from the Look AHEAD (Ac-
tion for Health in Diabetes) trial indicates
that intensive lifestyle intervention can
produce sustained weight loss and im-
provements in ﬁtness, glycemic control,
and cardiovascular disease risk factors in
people with type 2 diabetes (22). Identi-
ﬁcation of dysglycemia and early diagno-
sis of diabetes, along with intensive
treatment with lifestyle intervention for
both these groups, can be viewed as in-
separable in practice.
Other compelling arguments for an
earlyidentiﬁcationofdysglycemiaanddi-
abetes in some populations include the
level of risk, the age of onset of diabetes,
and the progression rate from dysglyce-
mia to diabetes. For example, people of
Asian origin (living in Asia or not) appear
to be at high risk of diabetes, develop the
disease at younger ages, and rapidly
progress from dysglycemia to diabetes
(23). In the India Diabetes Prevention
Project,58%ofpeoplewithimpairedglu-
cose tolerance progressed to diabetes
within 3 years (24), and even among peo-
ple with a fasting glucose 100–125 mg/dl
(impaired fasting glucose) in Chennai,
India, 9% convert to diabetes annually
(V.M. Mohan, personal communication).
Implementingapolicyofscreeningforboth
dysglycemia and diabetes may be poten-
tially cost-saving or cost-neutral; within a
3-year horizon and in a health system per-
spective,screeningandpreventivemanage-
mentfordysglycemiaanddiabetestogether
was found to be cost-saving, relative to no
screening, in one regional study (25).
There may be strong reasons to seri-
ously consider active identiﬁcation and
earlytreatmentofdysglycemiaanddiabe-
tes, especially for speciﬁc population
groups at very high risk (e.g., Asians,
younger people, other ethnic groups at
high risk) to potentially avoid the intrac-
tablecomplicationsthatcoincidewiththe
subsequent stages of diabetes. Before a
policy of active identiﬁcation can be im-
plemented, however, it is important to
carefully weigh the opportunity costs and
system capacity. Currently, even those
known to have diabetes receive subopti-
mal care in general, and an active identi-
ﬁcation policy will add considerable
pressures on the system by adding a large
number of hitherto undiagnosed cases and
alsobringingsubstantialnumberswithdys-
glycemia to the attention of the system.
Health care systems, in general, will not
havethecapacitytodealwiththeadditional
workload and the necessity to deliver the
appropriate treatment of newly diagnosed
diabetes and dysglycemia that will arise
with increased testing. Very few systems
currently have the orientation and re-
sources to deliver appropriate lifestyle or
other preventive interventions.
Regardless of the improvements in
the availability of low-cost, convenient
tests, such as POC capillary glucose tests
or the increasing evidence favoring the
beneﬁts of screening for type 2 diabetes,
any policy to implement active identiﬁca-
tion of diabetes/dysglycemia should not
be viewed lightly. It will be a huge under-
takingandadauntingtaskformosthealth
care systems, and, if done badly, could
cause more harm than good. Despite
overwhelming evidence for the preven-
tion of type 2 diabetes, even rich devel-
oped countries such as the U.S. are
grappling with how to integrate identiﬁ-
cation of high risk with lifestyle interven-
tion into a large, fragmented curative-
focused expensive health care system in
which delivery of uniform high-quality
care to all people with diagnosed diabetes
also remains a challenge. Some recent
progress has been made in the U.S. by
innovativelymergingincentives(e.g.,get-
ting health insurance plans to reimburse
lifestyle interventions) with community
resources (e.g., use of community part-
ners like the YMCA) (26) and also in Fin-
land (27) to advance the prevention of
type 2 diabetes and its complications.
At the same time, as the transitioning
economies of LMICs like India and China
continue to grow rapidly, they both expe-
riencethegrowingburdenofdiabetesand
willlikelyinvestinhealthandhealthcare.
This may be a green-ﬁeld opportunity to
use a policy of active identiﬁcation of di-
abetesanddysglycemiaasameanstopro-
pel health care toward an innovative
preventive orientation for noncommuni-
cable diseases (NCDs). For example, pri-
marypreventionfortype2diabetescould
serve as the entry point for broader NCD
prevention, as most chronic diseases
share the same risk factors (i.e., physical
activity,healthynutrition,smokingcessa-
tion) (28). Wise experimentation with,
Narayan and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 245and evaluation of, innovative and inte-
grated prevention-oriented low-cost
health care models may allow rapidly
transitioning LMICs to leapfrog the long-
established developed countries in terms
of realigning their systems at a nascent
stage and also help avoid and forestall
largehealthandeconomicburdensdueto
diabetesandotherNCDs.Anystrategyfor
early identiﬁcation of type 2 diabetes and
dysglycemia should be within the context
ofpolicytostrengthenandreorienthealth
systems, but the time for action in eco-
nomically fast growing LMICs is now.
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